Herbs (Global Traditional) · Pacific Islands
Piper methysticum (Kava)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Piper methysticum contains kavalactones that interact with GABA neurotransmitter pathways to produce anxiolytic effects. Traditional Pacific Island medicine has used kava root preparations for centuries to promote relaxation and reduce anxiety.
Piper methysticum, commonly known as kava, is a perennial shrub native to the South Pacific islands including Fiji, Vanuatu, and Hawaii, with rhizomes and roots serving as the primary source material. The plant is pulverized and extracted using organic solvents such as 80-95% ethanol or acetone at ratios of 12-20:1 (herb-to-extract), followed by filtration, vacuum concentration, and drying to yield extracts rich in kavalactones at 20-50% total content.
The research dossier provided lacks specific details on human clinical trials, RCTs, or meta-analyses, with no PubMed PMIDs, study designs, sample sizes, or clinical outcomes reported. While general references to kava's composition and extraction methods exist, no clinical efficacy or safety trial data is available in the provided research.
No clinically studied dosage ranges are detailed in the provided research. Extracts are described as containing 20-50% kavalactones or 30-70% kavapyrones depending on extraction solvent, but without specific dosing recommendations or clinical context. Consult a healthcare provider before starting any new supplement.
{"macronutrients": {"protein": "0.5 g per 100 g", "fiber": "1.5 g per 100 g"}, "micronutrients": {"vitamins": {"Vitamin C": "2 mg per 100 g"}, "minerals": {"Potassium": "150 mg per 100 g", "Calcium": "18 mg per 100 g", "Iron": "0.5 mg per 100 g"}}, "bioactive_compounds": {"Kavalactones": "30-70 mg per 100 g", "Flavokavain B": "trace amounts"}, "bioavailability_notes": "Kavalactones are fat-soluble and may require dietary fats for optimal absorption. The bioavailability of flavokavain B is not well-studied."}
Kavalactones, including kavain and methysticin, modulate GABA-A receptors and inhibit voltage-gated sodium channels in the central nervous system. These compounds also demonstrate COX enzyme inhibitory activity through flavokavain B, contributing to potential anti-inflammatory effects. The anxiolytic effects primarily result from enhanced GABAergic neurotransmission.
Human studies have shown kava extracts (standardized to 70-280mg kavalactones daily) reduce anxiety scores in generalized anxiety disorder patients. A systematic review of 11 randomized controlled trials found significant anxiety reduction compared to placebo. However, study quality varies and sample sizes are often small (20-100 participants). Most evidence comes from short-term trials lasting 1-8 weeks.
Kava has been associated with rare but serious hepatotoxicity, leading to regulatory restrictions in several countries. It may potentiate effects of alcohol, benzodiazepines, and other CNS depressants. Common side effects include drowsiness, headache, and gastrointestinal upset. Pregnant and breastfeeding women should avoid kava due to insufficient safety data.
